Search Result for "brain tumors"
Clinical Trial

A phase 1b/2, open-label, safety, tolerability and efficacy study of NC410 plus pembrolizumab for participants with advanced unresectable and/or metastatic immune checkpoint inhibitor (ICI) refractory solid tumors or ICI naive MSS/MSI-low solid tumors (CT

This is an open-label, non-randomized, Phase 1b/2 study to determine the safety and tolerability of NC410 when combined with a standard dose of Pembrolizumab. This study will also assess the clinical benefit of combination therapy in participants with advanced unresectable and/or metastatic ICI refractory solid tumors OR ICI naïve MSS/MSI-low solid tumors

Clinical Trial

A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan and
Pembrolizumab Versus Treatment of Physician’s Choice and Pembrolizumab
in Patients With Previously Untreated, Locally Advanced Inoperable or
Metastatic Triple-Negative Breast Cancer, W

This is an international, multicenter, open-label, randomized, Phase 3 study in patients with locally advanced, inoperable, or metastatic triple-negative breast cancer (mTNBC) who have not received previous therapy for advanced disease and whose tumors are PD-L1 positive (defined using the PD-L1 IHC 22C3 assay as tumors with a combined positive score [CPS] ≥ 10) at screening.